SciELO - Scientific Electronic Library Online

 
vol.141 issue3Analysis of ambulatory consultation length in medical clinicsDefault mode network and Alzheimer's disease author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Revista médica de Chile

Print version ISSN 0034-9887

Abstract

ACEVEDO, Francisco; HERRERA, María Elisa; MADRID, Jorge  and  SANCHEZ, César. Neoadyuvant endocrine therapy in breast cancer. Rev. méd. Chile [online]. 2013, vol.141, n.3, pp.367-374. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872013000300013.

Neoadjuvant chemotherapy is an accepted strategyforpatients with locally advanced breast cáncer. This approach increases the possibilities ofconservative treatment and improves the resectability rates ofinitially unresectable tumors. In addition, preoperative systemic therapy allows the evaluation of prognostic and predictive factors, dynamically and in vivo. Since over 80% ofthese tumors express estrogen receptors (ER), endocrine therapy seems a logical treatment to employ in the neoadjuvant setting. The advent ofnew drugs that regúlate the ERfunction, along with the results of severa! clinical studies with the use of neoadjuvant endocrine therapy, support the feasibility and safety of utilizing this strategy before surgery. We herein analyze the available clinical evidence about the use of neoadjuvant therapy aiming to regúlate the activity ofthe ER. We also discuss the valué of predictive factors that could help the oncologist to select those patients most likely to benefit from this approach and the role of endocrine therapy as a research instrument.

Keywords : Breast neoplasms; Chemotherapy; adjuvant; Receptors; estrogen.

        · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License